Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy
Esophageal and Gastric Varices
About this trial
This is an interventional treatment trial for Esophageal and Gastric Varices focused on measuring Terlipressin, Liver Cirrhosis, Esophageal and Gastric Varices,, Collateral Circulations
Eligibility Criteria
Inclusion Criteria:
- Patients of 18 years and older
- Both genders,
- Diagnosis of liver cirrhosis with a Child-Pugh score ≤ 11 (class B or C)
- Acute variceal bleeding were included
Exclusion Criteria:
- Patients with contraindications to terlipressin (pregnancy, breastfeeding, or severe cardiopulmonary diseases),
- Presence of sepsis,
- Multi-organ failure,
- The requirement of continuous ionotropic or ventilatory support,
- Bleeding disorders,
- Hepatocellular carcinoma or other extrahepatic malignanc.
Sites / Locations
- Centro Médico Nacional de Occidente
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
24-h group
72-h group
The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe